Characteristics of rofecoxib study subjects (n = 16)*
| FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; HbCO, carbomonoxyhaemoglobin; PEF, peak expiratory flow; FEF25–75, mid forced expiratory flow. | |
| *Data refer to patients who completed the study and are expressed as mean (SE). | |
| †All the patients had a smoking history of more than 10 pack years. | |
| ‡Atopy was an exclusion criterion. Absence of atopy was confirmed by skin prick testing. | |
| ¶All values are <2.6%. One patient was excluded from the study because of recent smoking exposure on visit 3 (HbCO 4.6%) and COPD exacerbation. | |
| Age (years) | 68 (2) |
| F/M | 6/10 |
| Smoking† | Ex-smokers |
| Arterial HbCO (%) | 0.7 (0.2)¶ |
| Pack years | >10 |
| FEV1 (l) | 1.51 (0.11) |
| FVC (l) | 2.82 (0.18) |
| FEV1 (% pred) | 59.6 (3.4) |
| FVC (% pred) | 85.8 (3.8) |
| FEV1/FVC (%) | 54.4 (2.6) |
| PEF (l/s) | 4.25 (0.34) |
| PEF (% pred) | 58.7 (4.2) |
| FEF25–75 (l/s) | 0.58 (0.07) |
| FEF25–75 (% pred) | 19.4 (2.5) |
| Change in FEV1 post-bronchodilator (% pred) | 2.2 (1.4) |
| Atopy‡ | No |
| Treatment | |
| β2 agonists | 5 |
| Anticholinergics | 4 |